Description Rontalizumab is a recombinant humanized monoclonal antibody to interferon alpha, which recognizes and neutralizes IFN alpha subtypes.
Development Status A Phase II clinical trial evaluating rontalizumab for systemic lupus erythematosus is ongoing.
Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.
National Institutes of Health Website: www.clinicaltrials.gov
February 2010